Investing in tomorrow's world: 225 Binney Street
We believe 225 Binney Street is a great example of our commitment to investing in real estate assets for tomorrow’s world.
We are focused on investment strategies and opportunities which safeguard and enhance value for our clients, whilst making a lasting and positive difference in the cities of tomorrow.
We acquired a 75% stake of 225 Binney Street located in Cambridge, Massachusetts, US, in 2015, from Alexandria Real Estate Equities, the largest office REIT solely focused on science and technology campuses. The investment represented our first entry into this exciting and growing arena.
Cambridge is home to a dynamic biotech industry within Boston’s innovation hub. The exposure to this sub-sector allows diversification beyond traditional office properties that cater to more typical office tenants in technology, finance, law or media industries.
The 305,000 sq ft (28,000 sq m) property is comprised of a six-storey, Class-A office building, and two renovated, historic brick-and-beam buildings. The building has achieved LEED Gold certification, in recognition of its efficient and environmentally-friendly construction and operation. The property is 100% net-leased through 2028 to Biogen, a multi-national bio-technology company specialising in the development of new drug therapies.
This material is provided for informational or educational purposes only and does not constitute a solicitation of any securities in any jurisdiction in which such solicitation is unlawful or to any person to whom it is unlawful. Moreover, it neither constitutes an offer to enter into an investment agreement with the recipient of this document nor an invitation to respond to it by making an offer to enter into an investment agreement.
This material may contain “forward-looking” information that is not purely historical in nature. Such information may include projections, forecasts, estimates of yields or returns, and proposed or expected portfolio composition. Moreover, certain historical performance information of other investment vehicles or composite accounts managed by Nuveen may be included in this material and such performance information is presented by way of example only. No representation is made that the performance presented will be achieved, or that every assumption made in achieving, calculating or presenting either the forward-looking information or the historical performance information herein has been considered or stated in preparing this material. Any changes to assumptions that may have been made in preparing this material could have a material impact on the investment returns that are presented herein by way of example.
This material is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The information and opinions contained in this material are derived from proprietary and non-proprietary sources deemed by Nuveen to be reliable, and not necessarily all-inclusive and are not guaranteed as to accuracy. There is no guarantee that any forecasts made will come to pass. Company name is only for explanatory purposes and does not constitute as investment advice and is subject to change. Any investments named within this material may not necessarily be held in any funds/accounts managed by Nuveen. Reliance upon information in this material is at the sole discretion of the reader. Views of the author may not necessarily reflect the view s of Nuveen as a whole or any part thereof.
Past performance is not a guide to future performance. Investment involves risk, including loss of principal. The value of investments and the income from them can fall as well as rise and is not guaranteed. Changes in the rates of exchange between currencies may cause the value of investments to fluctuate.
This information does not constitute investment research as defined under MiFID.